Perbandingan Nilai mMRC, Cat, Tes 6 Menit Berjalan Dan Nilai Faal Paru pada Pasien Penyakit Paru Obstruktif Kronik (PPOK) Stabil yang Diberikan Inhaler Tiotropium dan Inhaler Indacaterol + Glycopyrronium di Rumah Sakit Prof Dr Chairuddin P. Lubis

Abstract

Background and Objectives : Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that has a significant impact on patients' quality of life and functional capacity. Bronchodilator inhalers such as tiotropium and indacaterol+glycopyrronium combination are used as therapy to reduce symptoms and improve lung function in COPD patients. Comparison of the effectiveness between these two types of inhalers in reducing symptoms and affecting lung function and functional capacity still needs to be studied further. This study aims to analyze the comparison of the mMRC scale, CAT score, six-minute walking test (6MWT) results, and pulmonary function values in stable COPD patients receiving tiotropium inhalers compared to the combination of indacaterol + glycopyrronium. Methods: This study used a cross-sectional design with an analytic observational method. The subjects were stable COPD patients who received tiotropium inhaler (n=54) or indacaterol+glycopyrronium combination (n=56) at Prof dr Chairuddin P. Lubis Hospital since September-October 2024. The mMRC, CAT, six-minute walking test (6MWT), and lung function values (FEV1/FVC, FEV1, FVC) were observed. Statistical tests used included Wilcoxon test for non-normally distributed data and independent t-test for normally distributed data. Results: From the results of the study, there were no significant differences between the tiotropium and indacaterol + glycopyrronium groups in the parameters of FEV1 / FVC, FEV1, FVC, CAT score, and six-minute walking test results (p>0.05). Patient demographics showed balanced characteristics between the two groups, with most patients being in the age range of 60-69 years and having CAT scores showing mild to moderate symptoms. Conclusion: The results of this study show that there is no significant difference in terms of functional capacity, quality of life, and lung fauna between COPD patients receiving tiotropium compared to the combination of indacaterol+glycopyrronium. Therefore, the selection of bronchodilator therapy can be adjusted based on individual patient preferences and conditions without having to maintain one option as superior.